On 3 April 2025, Mendus has announced that the company presented data from its proprietary DCOne platform at the Immunotherapy of Cancer Conference. The presentation showcased the potential of the platform to expand ovarian cancer tumour-infiltrating lymphocytes (TIL), and overcome key hurdles in the ...Den vollständigen Artikel lesen ...
© 2025 Edison Investment Research